信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种

智通财经03-30

智通财经APP获悉，3月29日，中国国家药监局药品审评中心(CDE)官网公示，信达生物(01801)IBI310(一款抗CTLA-4单抗)及信迪利单抗(IBI308，抗PD-1单抗)两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。根据信达生物近日发布的新闻稿，IBI310联合信迪利单抗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2423214294?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-30 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2423214294","market":"sh","top_or_hot":-1,"title":"信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月29日，中国国家药监局药品审评中心(CDE)官网公示，信达生物(01801)IBI310(一款抗CTLA-4单抗)及信迪利单抗(IBI308，抗PD-1单抗)两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。根据信达生物近日发布的新闻稿，IBI310联合信迪利单抗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1096655.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-30 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1096655.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月29日，中国国家药监局药品审评中心(CDE)官网公示，信达生物(01801)IBI310(一款抗CTLA-4单抗)及信迪利单抗(IBI308，抗PD-1单抗)两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。根据信达生物近日发布的新闻稿，IBI310联合信迪利单抗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1096655.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1096655.html","article_id":"2423214294","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2423214294","pubTimestamp":1711763080,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月29日，中国国家药监局药品审评中心官网公示，信达生物IBI310及信迪利单抗两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性或错配修复基因缺陷型结肠癌的新辅助治疗。据悉，IBI310是信达生物自主研发的重组全人源抗CTLA-4单克隆抗体注射液。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4023":"应用软件","BK1583":"高瓴概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","01801":"信达生物","BK1589":"北水核心资产","BK1161":"生物科技","PD":"PagerDuty, Inc."},"translate_title":"Cinda Bio (01801) anti-CTLA-4 monoclonal antibody + anti-PD-1 monoclonal antibody is planned to be included in the breakthrough treatment variety","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1,"PD":1},"content_text":"智通财经APP获悉，3月29日，中国国家药监局药品审评中心(CDE)官网公示，信达生物(01801)IBI310(一款抗CTLA-4单抗)及信迪利单抗(IBI308，抗PD-1单抗)两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。根据信达生物近日发布的新闻稿，IBI310联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌(cT4或cN+期)患者的随机、对照、多中心3期临床研究(Neoshot)，已经于今年3月完成中国首例受试者给药。据悉，IBI310是信达生物自主研发的重组全人源抗CTLA-4单克隆抗体注射液。该产品能特异性结合CTLA-4，从而阻断CTLA-4介导的T细胞抑制，促进T细胞的激活和增殖，提高肿瘤免疫反应，达到抗肿瘤的效果。信迪利单抗是信达生物和礼来(Eli Lilly and Company)公司共同合作研发的抗PD-1单抗，已经在中国获批七项适应症，涵盖经典型霍奇金淋巴瘤、非小细胞肺癌、肝细胞癌、食管鳞癌、胃癌等。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2423214294"}